GLOBUS MEDICAL INC - A (GMED) Stock Price, Forecast & Analysis

NYSE:GMED • US3795772082

93.4 USD
+2.81 (+3.1%)
At close: Feb 23, 2026
93.75 USD
+0.35 (+0.37%)
Pre-Market: 2/24/2026, 8:29:47 AM

GMED Key Statistics, Chart & Performance

Key Statistics
Market Cap12.50B
Revenue(TTM)2.77B
Net Income(TTM)423.78M
Shares133.84M
Float110.37M
52 Week High101.4
52 Week Low51.79
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)3.56
PE26.24
Fwd PE21.48
Earnings (Next)02-24
IPO2012-03-08
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
GMED short term performance overview.The bars show the price performance of GMED in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40 50

GMED long term performance overview.The bars show the price performance of GMED in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of GMED is 93.4 USD. In the past month the price increased by 0.95%. In the past year, price increased by 16.28%.

GLOBUS MEDICAL INC - A / GMED Daily stock chart

GMED Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to GMED. When comparing the yearly performance of all stocks, GMED turns out to be only a medium performer in the overall market: it outperformed 65.19% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
GMED Full Technical Analysis Report

GMED Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to GMED. GMED has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GMED Full Fundamental Analysis Report

GMED Financial Highlights

Over the last trailing twelve months GMED reported a non-GAAP Earnings per Share(EPS) of 3.56. The EPS increased by 22.76% compared to the year before.


Industry RankSector Rank
PM (TTM) 15.3%
ROA 8.32%
ROE 9.63%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%42.17%
Sales Q2Q%22.91%
EPS 1Y (TTM)22.76%
Revenue 1Y (TTM)11.75%
GMED financials

GMED Forecast & Estimates

22 analysts have analysed GMED and the average price target is 107.03 USD. This implies a price increase of 14.59% is expected in the next year compared to the current price of 93.4.

For the next year, analysts expect an EPS growth of 25.18% and a revenue growth 16.37% for GMED


Analysts
Analysts78.18
Price Target107.03 (14.59%)
EPS Next Y25.18%
Revenue Next Year16.37%
GMED Analyst EstimatesGMED Analyst Ratings

GMED Ownership

Ownership
Inst Owners108.37%
Ins Owners0.71%
Short Float %3.74%
Short Ratio2.96
GMED Ownership

GMED Latest News, Press Relases and Analysis

All GMED news

GMED Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES20.08200.474B
ISRG INTUITIVE SURGICAL INC48.15174.759B
SYK STRYKER CORP25.44147.128B
BSX BOSTON SCIENTIFIC CORP21.23110.292B
BDX BECTON DICKINSON AND CO11.752.52B
IDXX IDEXX LABORATORIES INC42.0649.757B
EW EDWARDS LIFESCIENCES CORP27.7347.84B
GEHC GE HEALTHCARE TECHNOLOGY16.738.219B
RMD RESMED INC21.2437.992B
DXCM DEXCOM INC29.0228.573B

About GMED

Company Profile

GMED logo image Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The company is headquartered in Audubon, Pennsylvania and currently employs 5,300 full-time employees. The company went IPO on 2012-03-08. The firm offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. The company provides solutions that facilitate both open and minimally invasive surgery techniques. The company includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.

Company Info

GLOBUS MEDICAL INC - A

2560 General Armistead Ave

Audubon PENNSYLVANIA 19403 US

CEO: David M. Demski

Employees: 5300

GMED Company Website

GMED Investor Relations

Phone: 16109301800

GLOBUS MEDICAL INC - A / GMED FAQ

What does GLOBUS MEDICAL INC - A do?

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The company is headquartered in Audubon, Pennsylvania and currently employs 5,300 full-time employees. The company went IPO on 2012-03-08. The firm offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. The company provides solutions that facilitate both open and minimally invasive surgery techniques. The company includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.


Can you provide the latest stock price for GLOBUS MEDICAL INC - A?

The current stock price of GMED is 93.4 USD. The price increased by 3.1% in the last trading session.


What is the dividend status of GLOBUS MEDICAL INC - A?

GMED does not pay a dividend.


What is the ChartMill technical and fundamental rating of GMED stock?

GMED has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What do analysts say about GLOBUS MEDICAL INC - A (GMED) stock?

22 analysts have analysed GMED and the average price target is 107.03 USD. This implies a price increase of 14.59% is expected in the next year compared to the current price of 93.4.


Is GLOBUS MEDICAL INC - A (GMED) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GMED.


How many employees does GLOBUS MEDICAL INC - A have?

GLOBUS MEDICAL INC - A (GMED) currently has 5300 employees.